Stock MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
7.61 USD -1.55% Intraday chart for Maravai LifeSciences Holdings, Inc. -11.41% +16.18%
Apr. 18 Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego MT
Apr. 10 Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target MT

Evolution of the average Target Price on Maravai LifeSciences Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

76.wb9_ONRZfVwbkipErm2THAf_w9yTsjLN7i-yQ0U1VWw.s482ceYeMA5cpV0W-BjqfXSF7qyj0Xb-jFjRMxJZeA-I-DphnhVEEHLrEg~9ec5735994370bb8e73a6648f8c9cd32

Analyst Recommendations on Maravai LifeSciences Holdings, Inc.

Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating MT
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating MT
Stifel Trims Price Target on Maravai LifeSciences to $10 From $11, Maintains Buy Rating MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating MT
BofA Securities Upgrades Maravai LifeSciences to Buy From Neutral MT
Goldman Sachs Trims Maravai LifeSciences Holdings' Price Target to $7 From $8, Maintains Neutral Rating MT
Morgan Stanley Trims Price Target on Maravai LifeSciences to $11 From $12, Maintains Overweight Rating MT
UBS Adjusts Maravai LifeSciences Price Target to $6 From $12, Maintains Neutral Rating MT
Deutsche Bank Adjusts Maravai LifeSciences Price Target to $10 From $17, Maintains Buy Rating MT
UBS Trims Price Target on Maravai LifeSciences to $12 From $12.75, Reiterates Neutral Rating MT
UBS Adjusts Maravai LifeSciences Price Target to $12.75 From $14, Maintains Neutral Rating MT
Deutsche Bank Adjusts Maravai LifeSciences Price Target to $17 From $23, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Maravai LifeSciences to $12 From $27, Keeps Overweight Rating MT
Stifel Adjusts Price Target on Maravai LifeSciences to $12 From $17, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target on Maravai LifeSciences to $8 From $12, Keeps Neutral Rating MT
Baird Adjusts Price Target on Maravai LifeSciences to $11 From $18, Keeps Outperform Rating MT
Credit Suisse Adjusts Maravai LifeSciences Holdings' Price Target to $11 From $14, Keeps Neutral Rating MT
RBC Cuts Price Target on Maravai LifeSciences Holdings to $18 From $20 Amid Lower Guidance, Keeps Outperform Rating MT
KeyBanc Downgrades Maravai LifeSciences Holdings to Sector Weight From Overweight Amid Limited Visibility, Lack of Catalysts MT
UBS Adjusts Price Target on Maravai LifeSciences Holdings to $14 From $15, Maintains Neutral Rating MT
Credit Suisse Downgrades Maravai LifeSciences Holdings to Neutral From Outperform, Notes Decelerating Core Growth; Cuts PT to $14 From $18 MT
Morgan Stanley Adjusts Price Target on Maravai LifeSciences Holdings to $27 From $29, Maintains Overweight Rating MT
Goldman Sachs Downgrades Maravai LifeSciences Holdings to Neutral From Buy, Adjusts Price Target to $13 From $16 MT
Deutsche Bank Adjusts Maravai LifeSciences Price Target to $23 From $25, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
7.61 USD
Average target price
9.785 USD
Spread / Average Target
+28.57%
High Price Target
15 USD
Spread / Highest target
+97.11%
Low Price Target
6.5 USD
Spread / Lowest Target
-14.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Maravai LifeSciences Holdings, Inc.

Craig-Hallum
RBC Capital Markets
UBS
Stifel Nicolaus
BofA Securities
Goldman Sachs
Morgan Stanley
Deutsche Bank Securities
Credit Suisse
Baird
KeyBanc Capital Markets
Jefferies & Co.

Ratings for Maravai LifeSciences Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MRVI Stock
  4. Consensus Maravai LifeSciences Holdings, Inc.